...
首页> 外文期刊>Journal of gastroenterology and hepatology >Effects of a probiotic fermented milk on functional constipation: A randomized, double-blind, placebo-controlled study
【24h】

Effects of a probiotic fermented milk on functional constipation: A randomized, double-blind, placebo-controlled study

机译:益生菌发酵乳对功能性便秘的影响:一项随机,双盲,安慰剂对照研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Aim: Evidence suggests that probiotics reduce certain constipation-related symptoms. Lactobacillus casei strain Shirota has never been tested as treatment for functional constipation in otherwise-healthy subjects. To evaluate the efficacy of this probiotic among adults with functional constipation was aimed. Methods: Subjects with functional constipation (Rome II-defined) were randomized to intake L.casei strain Shirota fermented milk or placebo once daily for 4 weeks under double-blind condition. Primary outcomes were constipation severity and stool frequency; secondary outcomes were stool consistency and quantity. Results: In intent-to-treat population, compared with baseline, constipation severity and stool frequency improved in both probiotic (n=47) and control groups (n=43), but improvements were comparable in both groups at week 4 (α=5% level). In probiotic group, stool consistency and quantity at week 4 improved significantly versus baseline but not versus control. Considering that the study agent is non-pharmaceutical and the purpose of supplementation is for long-term effect, re-evaluation at α=10% was conducted, which showed significant improvement in constipation severity at week 4 (P=0.058). Magnitude of the probiotic effect on stool consistency was small but grew over time, d=0.19, 95% confidence interval 0.00-0.35 (Week 4), d=0.29, 95% confidence interval 0.11-0.52 (postintervention). Post-hoc exploratory analysis suggests incomplete evacuation may decrease with probiotic intake. Conclusions: Four-week administration of L.casei strain Shirota did not alleviate constipation severity or stool frequency, consistency, and quantity when compared with control. With re-evaluation at α=10% level, improvement in constipation severity was significant at week 4. To obtain conclusive results, further studies with longer intervention are warranted.
机译:背景与目的:有证据表明益生菌可减轻某些便秘相关症状。干酪乳杆菌菌株Shirota从未在其他健康受试者中用作功能性便秘的治疗方法。目的是评估这种益生菌在患有功能性便秘的成年人中的功效。方法:将具有功能性便秘(罗马II级定义)的受试者随机分为双盲条件,每天摄入干酪乳杆菌菌株Shirota发酵乳或安慰剂,持续4周。主要结局为便秘严重程度和大便次数。次要结果是粪便的稠度和数量。结果:在意向性治疗人群中,与基线相比,益生菌组(n = 47)和对照组(n = 43)的便秘严重程度和粪便频率均得到改善,但两组在第4周时的改善程度相当(α= 5%的水平)。在益生菌组中,第4周的粪便稠度和数量与基线相比有显着改善,但与对照组相比则没有改善。考虑到研究药物是非药物的,并且补充的目的是为了长期有效,因此在α= 10%的情况下进行了重新评估,结果显示便秘严重程度在第4周有显着改善(P = 0.058)。益生菌对粪便稠度的影响很小,但随时间增长,d = 0.19,95%置信区间为0.00-0.35(第4周),d = 0.29,95%置信区间为0.11-0.52(干预后)。事后探索性分析表明,随着益生菌的摄入,不完全疏散可能会减少。结论:与对照组相比,给予干酪乳杆菌Shirota的四周时间不能减轻便秘的严重程度或粪便频率,稠度和数量。在α= 10%的水平上进行重新评估后,便秘严重程度的改善在第4周显着改善。为了获得结论性结果,有必要在更长的干预时间内进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号